Research interests include Glioma Diagnosis and Treatment, Ferroptosis and cancer prognosis, Cancer, Hypoxia, and Metabolism, and Ubiquitin and proteasome pathways.
A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.
Journal of Clinical Oncology2013cited by 61position: middledoi